Roquinimex

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Roquinimex
Roquinimex.svg
Clinical data
ATC code
Pharmacokinetic data
Elimination half-life26-42 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.163.758 Edit this at Wikidata
Chemical and physical data
FormulaC18H16N2O3
Molar mass308.331 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity. It also inhibits angiogenesis and reduces the secretion of TNF alpha.

Roquinimex has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes. Several trials have been terminated due to serious cardiovascular toxicity.

Synthesis[edit]

Roquinimex synthesis:[1]

Ethyl 2-(methylamino)benzoate is condensed with ethyl malonate. Amine-ester interchange of that compound with N-methylaniline results in formation of the amide roquinimex.

References[edit]

  1. ^ E. Eriksoo et al., EP 59698 ; eidem, U.S. Patent 4,738,971 (1982, 1988 both to AB Leo).